Ernest Asante‐Appiah

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 84 篇 · 总被引 2684 次 · h-index 28

代表论文

• Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development (2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 49)
• Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (2022 · Antimicrobial Agents and Chemotherapy · 被引 47)
• Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials (2023 · The Lancet HIV · 被引 34)
• Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance (2022 · Antimicrobial Agents and Chemotherapy · 被引 28)
• Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C‐CORAL study (2018 · Journal of Gastroenterology and Hepatology · 被引 26)
• Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates (2021 · Antimicrobial Agents and Chemotherapy · 被引 23)